Waverley Pharma Inc. WAVE.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -20.56% | -24.28% | -34.18% | 1,120.12% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -20.56% | -24.28% | -34.18% | 1,120.12% | -- |
| Cost of Revenue | -2.26% | -19.77% | -29.43% | 2,536.84% | -- |
| Gross Profit | -40.63% | -32.09% | -40.21% | 366.36% | -- |
| SG&A Expenses | 17.60% | 38.19% | -3.92% | 236.29% | 24.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.00% | 2.97% | -18.98% | 82.80% | 21.99% |
| Operating Income | -1,031.08% | -544.53% | -47.83% | 18.53% | 103.33% |
| Income Before Tax | -403.48% | -374.10% | -203.65% | 14.24% | 92.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -403.48% | -374.10% | -203.65% | 13.64% | 92.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -403.48% | -374.10% | -203.65% | 13.64% | 92.02% |
| EBIT | -1,031.08% | -544.53% | -47.83% | 18.53% | 103.33% |
| EBITDA | -343.95% | -6,233.33% | -53.99% | 27.07% | 113.63% |
| EPS Basic | -375.00% | -340.00% | -188.89% | 13.51% | 91.49% |
| Normalized Basic EPS | -500.00% | -366.67% | -220.00% | 13.04% | 93.10% |
| EPS Diluted | -375.00% | -340.00% | -188.89% | 56.16% | 94.52% |
| Normalized Diluted EPS | -500.00% | -366.67% | -220.00% | 13.04% | 93.10% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |